DQHTFI is proposed, a fine-grained interaction prediction framework for drug–target interaction classification and binding affinity regression that employs BRICS fragments and Pfam functional domains as the basic interaction units and jointly learns semantic and structural representations.
DeepGCL is presented, a novel multi-modal framework that leverages multi-view graph contrastive learning to capture latent representations of pocket-drug interactions and their underlying molecular determinants and underscores the effectiveness of multi-view learning paradigms in capturing the multifaceted nature of drug-target interactions.
Hongmei Wang, Shisen Sun, Mujin Li et al.· IEEE journal of biomedical a...· 0 citations
Experiments show that GraESM-FuseDTA achieves competitive overall performance and consistent advantages in ranking-oriented and variance-explanation metrics across warm start, drug cold start, target cold start, and strict pair cold start settings.
IHLO-DTI, a novel prediction model based on an improved hypergraph neural network and Laplacian matrix optimization, can effectively capture high-order many-to-many interactions between drugs and targets, improving prediction accuracy and robustness.
Guolongwei Dai, Tao Luo, Dandan Li et al.· ACS Synthetic Biology· 0 citations
Experiments demonstrate that HSAF-DDI achieves superior overall performance compared to state-of-the-art methods, indicating the critical role of fine-grained biological features in improving the DDI prediction performance.
Xiaoli Lin, Si-Yuan Zhang, Bo Li et al.· Journal of Chemical Informat...· 0 citations
Drug-target interaction (DTI) prediction is an important task in AI-driven drug discovery. Although recent biochemical representation learning methods have improved DTI prediction, their passive feature aggregation tends to favor dominant molecular patterns while suppressing weak yet binding-relevant signals, such as functional groups and residue-context patterns, limiting the modeling of multi-scale biochemical correspondences. To address this issue, we propose ProbeMatchDTI, a pattern-probe-driven framework comprising IterProbe and BindingProbe. IterProbe explicitly retains contextual states across refinement depths and uses learnable probes to select them at each position before cross-entity matching, thereby preserving weak biochemical patterns and strengthening associations among functional groups, local motifs, and molecular scaffolds. BindingProbe then characterizes cross-entity drug-protein complementarity at local biochemical-unit and whole-pair levels, jointly modeling fine-grained interactions and multi-scale correspondences while preserving weaker binding-relevant associations. Extensive experiments demonstrate the superiority of ProbeMatchDTI, achieving 2.0% and 0.5% higher AUC-ROC on BindingDB and DrugBank, respectively. Feature-level pattern analyses further characterize its probe-driven behavior in cross-scale biochemical pattern matching. We further connect ProbeMatchDTI predictions with an evidence-guided downstream drug-discovery workflow, demonstrating their utility for candidate refinement and validation planning. Our code is available at https://github.com/developer-hq/ProbeMatchDTI
Quan Hao, Meng-Yue Fan, Zifan Dong et al.· 0 citations
This work proposes GraphTransDTI, a synergistic hybrid framework that integrates a Graph Transformer to represent drug graph structures, a CNN-BiLSTM network to encode protein sequence context, and a Cross-Attention mechanism to model cross-domain interactions.
Vang V. Le, Mai Thi Anh Nhu, Pham Truong Viet Thong· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
